Financial FlexibilityOPKO is utilizing its newfound financial strength to repurchase common shares and convertible notes, indicating confidence in its financial position.
Profitability And GrowthOPKO's decision to focus on its strengths and to monetize a lab business that never really worked gives it a better chance to create long-term value for shareholders.
Strategic PartnershipsModeX Therapeutics entered into an exclusive worldwide license and collaboration agreement with Merck for the development of MDX-2201—a preclinical nanoparticle vaccine candidate targeting the Epstein-Barr virus.